Scarica l'app Stockscreener
46.70
4.07%
-2.02
Precedente Chiudi:
$48.72
Aprire:
$47.63
Volume 24 ore:
175.71K
Relative Volume:
0.12
Capitalizzazione di mercato:
$3.32B
Reddito:
-
Utile/perdita netta:
$-218.28M
Rapporto P/E:
-13.04
EPS:
-3.5803
Flusso di cassa netto:
$-186.55M
1 W Prestazione:
+0.47%
1M Prestazione:
-13.32%
6M Prestazione:
+106.50%
1 anno Prestazione:
+37.08%
Intervallo 1D:
$46.62
$48.64
Intervallo di 1 settimana:
$44.55
$49.33
Portata 52W:
$18.53
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Confronta VERA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
46.75 | 3.46B | 0 | -218.28M | -186.55M | -3.5803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-16 | Iniziato | BofA Securities | Buy |
| 2025-08-04 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
SG Americas Securities LLC Takes $911,000 Position in Vera Therapeutics, Inc. $VERA - MarketBeat
Buyout Rumor: Is Vera Therapeutics Inc vulnerable to short sellersWeekly Investment Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Insider Buy: Whats the analyst consensus on Vera Therapeutics IncTake Profit & Safe Capital Investment Plans - baoquankhu1.vn
Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock By Investing.com - Investing.com Canada
Published on: 2026-01-16 22:59:19 - baoquankhu1.vn
Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? - sharewise.com
Understanding the Setup: (VERA) and Scalable Risk - Stock Traders Daily
Vera Therapeutics, Inc. (VERA) Stock Analysis: A 62% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Vera Therapeutics (NASDAQ:VERA) Shares Down 7.4%Here's Why - MarketBeat
Assessing Vera Therapeutics (VERA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Short report: Vera Therapeutics bears retreat as stock rallies - MSN
Does FDA Priority Review For Atacicept Reshape The Bull Case For Vera Therapeutics (VERA)? - Yahoo Finance
Will Vera Therapeutics Inc. stock split again soonJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - Улправда
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why Vera Therapeutics (VERA) Is Down 5.8% After FDA Priority Review Acceptance For AtaciceptAnd What's Next - Sahm
What risks investors should watch in Vera Therapeutics Inc. stockCEO Change & Free Expert Verified Stock Movement Alerts - Улправда
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Sahm
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Is Vera Therapeutics Inc. stock gaining market share2025 Growth vs Value & AI Powered Market Entry Ideas - Улправда
Upcoming EventsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Detailed Stock Data - FinancialContent
Vera Therapeutics, Inc.'s (NASDAQ:VERA) Shift From Loss To Profit - 富途牛牛
Will Vera Therapeutics Inc. stock attract ESG investorsRisk Management & AI Powered Market Entry Ideas - ulpravda.ru
Is Vera Therapeutics Inc. stock a safe buy before earningsJuly 2025 Reactions & Community Driven Trade Alerts - ulpravda.ru
Los Angeles Daily NewsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Stock Quote - FinancialContent
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ - openPR.com
Why Vera Therapeutics Stock Zoomed Higher Today - The Globe and Mail
FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review - Investing.com Nigeria
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review By Investing.com - Investing.com South Africa
Vera Therapeutics shares up 3% after co receives U.S. FDA priority review for kidney disease drug - marketscreener.com
Vera Therapeutics' Atacicept Receives FDA Priority Review for Treatment of IgAN with PDUFA Date Set for July 7, 2026 - Quiver Quantitative
Vera Therapeutics Announces U.S. FDA Granted Priority - GlobeNewswire
Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application - TradingView — Track All Markets
FDA Expedites Approval of Vera’s Home-Based Kidney Medication - Bitget
Wells Fargo sees short squeeze ahead: here are three stocks to play it - CryptoRank
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
These Bay Area drugmakers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
Quarterly Earnings: Will Vera Therapeutics Inc stock attract ESG investors2025 Market Trends & Accurate Technical Buy Alerts - moha.gov.vn
Stock Traders Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA) - MarketBeat
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading - ts2.tech
Vera Therapeutics announces $200M public offering - MSN
Entry Recap: What risks investors should watch in Vera Therapeutics Inc stockJuly 2025 Momentum & Consistent Return Investment Signals - moha.gov.vn
Vera Therapeutics price target raised to $33 from $23 at Wedbush - MSN
50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB - MarketBeat
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):